In light of the angst and hand-wringing over the soaring costs of biologic drugs that are alleged to be contributing to the unsustainability of biologic treatments, the U.S. Food and Drug Administration (FDA) approval of the first biosimilar in the U.S. was welcome news to many.
In late January, the Department of Health and Human Services (HHS) announced that it would fundamentally reform how it pays providers for treatingMedicare patients in the coming years. Speeding up the transition from fee-for-service to pay-for-performance and forcing Medicare to commit to this payment
New laws and policies are being enacted globally to stem the growth of counterfeit and adulterated drugs caused by increases in globalization and the supply chain complexity.
On Oct. 31, the Centers for Medicare and Medicaid Services (CMS) issued the calendar year 2015 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory SurgicalCenter Payment System Policy Changes and Payment Rates final rule [CMS-1613-FC].
While the healthcare industry is currently experiencing an oversupply of the lifesaving immune globulin therapy, with demand growing at 6 percent to 8 percent a year, is it possible another shortage looms large?
Medicine has come into the electronic age with telemedicine, which provides wider reaching care in an era when there is a projected doctor shortage.
Today’s evolving healthcare delivery models increasingly require organized, careful multidisciplinary approach that supports the use of specialty medications.
There’s no doubt that complexity is the operational word for reimbursement, and this includes the rules and nuances that govern drugs and biologicals. Even though some healthcare practitioners’ sites may contract with an outside provider of billing services, it’s incumbent on the providers and their office staffs to know the background information on the requirements of what’s reimbursable.
A look at how an epidemiologist conducts an investigation into a measles outbreak shows just how complicated containing an outbreak can be.
New legislation, increased education, and high-tech tracking aim to curb the proliferation of compromised and counterfeit products in the pipeline.
Complexity is the operational word for reimbursement, and this includes the rules and nuances that govern drugs and biologicals. Here is a summary of important 2014 issues.
Allowing pharmacists to become more involved in patient care will reap benefits for patients and save healthcare dollars.